View Item 

Show simple item record

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity

dc.contributor.authorMatino, D.en_US
dc.contributor.authorLillicrap, D.en_US
dc.contributor.authorAstermark, J.en_US
dc.contributor.authorDolan, G.en_US
dc.contributor.authorKessler, C.en_US
dc.contributor.authorLambert, T.en_US
dc.contributor.authorMakris, M.en_US
dc.contributor.authorO'Donnell, J.en_US
dc.contributor.authorPipe, S.en_US
dc.contributor.authorSantagostino, E.en_US
dc.contributor.authorSaint‐remy, J.‐m.en_US
dc.contributor.authorSchramm, W.en_US
dc.contributor.authorIorio, A.en_US
dc.date.accessioned2014-03-05T18:18:59Z
dc.date.available2015-04-16T14:24:20Zen_US
dc.date.issued2014-03en_US
dc.identifier.citationMatino, D.; Lillicrap, D.; Astermark, J.; Dolan, G.; Kessler, C.; Lambert, T.; Makris, M.; O'Donnell, J.; Pipe, S.; Santagostino, E.; Saint‐remy, J.‐m. ; Schramm, W.; Iorio, A. (2014). "Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity." Haemophilia 20(2): 200-206.en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106092
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherHaemophiliaen_US
dc.subject.otherClotting Factor Concentratesen_US
dc.subject.otherImmunogenicityen_US
dc.subject.otherInhibitorsen_US
dc.titleSwitching clotting factor concentrates: considerations in estimating the risk of immunogenicityen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106092/1/hae12283.pdf
dc.identifier.doi10.1111/hae.12283en_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceSingleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell‐produced to baby hamster kidney cell‐produced recombinant factor VIII. Thromb Haemost 2007; 98: 1188 – 92.en_US
dc.identifier.citedreferenceKey NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439 – 48.en_US
dc.identifier.citedreferenceHoyer LW. Factor VIII inhibitors: a continuing problem. J Lab Clin Med 1993; 121: 385 – 7.en_US
dc.identifier.citedreferenceWight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418 – 35.en_US
dc.identifier.citedreferenceDarby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977‐99. J Thromb Haemost 2004; 2: 1047 – 54.en_US
dc.identifier.citedreferenceMcMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344 – 8.en_US
dc.identifier.citedreferenceKempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates Journal of thrombosis and haemostasis. Thromb Haemost 2006; 4: 2576 – 81.en_US
dc.identifier.citedreferenceAstermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18 ( Suppl 4 ): 38 – 42.en_US
dc.identifier.citedreferenceHay CRM, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367 – 70.en_US
dc.identifier.citedreferenceVermylen J, Peerlinck K. Epidemic of factor VIII inhibitors linked to factor VIII‐P. Acta Clin Belg 1991; 46: 419 – 20.en_US
dc.identifier.citedreferenceRosendaal FR, Nieuwenhuis HK, Van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180 – 6.en_US
dc.identifier.citedreferenceGiles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfusion Sci 1998; 19: 139 – 48.en_US
dc.identifier.citedreferenceRubinger M, Lillicrap D, Rivard GE et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281 – 6.en_US
dc.identifier.citedreferenceBaglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost 1998; 80: 1036 – 7.en_US
dc.identifier.citedreferenceRea C, Dunkerley A, Sørensen B, Rangarajan S. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full‐length FVIII treatment to B‐domain‐deleted r‐FVIII and back to full‐length FVIII. Haemophilia 2009; 15: 1237 – 42.en_US
dc.identifier.citedreferenceBacon CL, Singleton E, Brady B et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin‐free recombinant factor VIII product (ADVATE ® ). Haemophilia 2011; 17: 407 – 11.en_US
dc.identifier.citedreferenceGouw SC, Van der Bom JG, Auerswald G, Escuriola EC, Tedgard U, Van den Berg HM. Recombinant versus plasma‐derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693 – 7.en_US
dc.identifier.citedreferenceGouw SC, Van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231 – 9.en_US
dc.identifier.citedreferenceChristiansen MLS, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878 – 87.en_US
dc.identifier.citedreferenceStennicke HR, Kjalke M, Karpf DM et al. A novel B‐domain O‐glycoPEGylated FVIII (N8‐GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood Jan 18 2013; 121: 2108 – 16.en_US
dc.identifier.citedreferencePowell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031 – 7.en_US
dc.identifier.citedreferenceMakris M, Calizzani G, Fischer K et al. EUHASS: the European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 ( Suppl ): S22 – 5.en_US
dc.identifier.citedreferenceSiegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R. Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection. Hämostaseologie 2010; 30: S37 – 9.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae12283.pdf
Size:
113.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.